References
- Caligaris-Cappio F. Role of microenvironment in chronic lymphocytic leukeamia. Br J Haematol 2003; 123: 380–388
- Chiorazzi N, Rai K, Ferranini M. Chronic lymphocytic leukemia. N Eng J. Med 2005; 352: 804–815
- James C, Ugo V, Casadevall N, Constantinescu S, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546–554
- Martinez-Lostao L, Briones J, Forne I, Martinez-Gallo M, Ferrer B, Sierra J, et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46: 435–442
- Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
- Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK V617F mutation in polycythemia vera. Blood 2006, Epub ahead of print, DOI 10.1182/blood-2006-04-017392
- Levine R, Loriaux M, Huntly B, Loh M, Beran M, Stoffregen E, et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic blastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379
- Steensma D, Dewald G, Lasho T, Powell H, McClure R, Levine R, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207–1209
- Lee J W, Soung Y, Kim S, Nam S, Park W, Lee S, et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 2006; 47: 313–314
- Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2 V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962–18967
- Frank D, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT 3 constitutively phosphorylated on serine residues. J Clin Invest 1997; 100: 3140–3148
- Steensma D, McClure R F, Karp J E, Tefferi A, Lasho T L, Powell H L, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971–978